
## Victoria R Nachar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5222781/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective. Journal of Oncology Pharmacy Practice, 2022, , 107815522110724.	0.5	0
2	Incidence and risk factors for bacterial infection in newly diagnosed multiple myeloma patients undergoing treatment with bortezomib, lenalidomide, and dexamethasone (RVD) Journal of Clinical Oncology, 2022, 40, e20008-e20008.	0.8	0
3	Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases. Annals of Pharmacotherapy, 2021, 55, 697-704.	0.9	6
4	Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management. Supportive Care in Cancer, 2021, 29, 6505-6510.	1.0	8
5	Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 295-308.	0.2	0
6	Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2021, 62, 1-9.	0.6	2
7	Chemotherapy Remote Care Monitoring Program: Integration of SMS Text Patient-Reported Outcomes in the Electronic Health Record and Pharmacist Intervention for Chemotherapy-Induced Nausea and Vomiting. JCO Oncology Practice, 2021, 17, e1303-e1310.	1.4	9
8	Clinical controversies in the treatment of cancer-associated venous thromboembolism. Journal of Oncology Pharmacy Practice, 2021, 27, 939-953.	0.5	3
9	Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 691-698.	0.6	13
10	Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma. Journal of Oncology Pharmacy Practice, 2020, 26, 1248-1253.	0.5	4
11	Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. Critical Reviews in Oncology/Hematology, 2020, 148, 102897.	2.0	2
12	PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma. Lancet Oncology, The, 2019, 20, e188.	5.1	1
13	The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leukemia Research, 2018, 70, 91-96.	0.4	20